A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma
What is the purpose of this trial?
This phase II trial studies how well trametinib works in treating patients with epithelioid hemangioendothelioma that has spread to other places in the body, nearby tissue or lymph nodes, or cannot be removed by surgery. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Ages15 years and older
- Trial withNational Cancer Institute
- Start Date08/28/2018
- End Date12/30/2023
- Last Updated12/17/2018
- Study HIC#2000021708